In response to nutrients, energy sufficiency, hormones, and mitogenic agents, S6K1 phosphorylates several targets linked to translation. However, the molecular mechanisms whereby S6K1 is activated, encounters substrate, and contributes to translation initiation are poorly understood. We show that mTOR and S6K1 maneuver on and off the eukaryotic initiation factor 3 (eIF3) translation initiation complex in a signal-dependent, choreographed fashion. When inactive, S6K1 associates with the eIF3 complex, while the S6K1 activator mTOR/raptor does not. Cell stimulation promotes mTOR/raptor binding to the eIF3 complex and phosphorylation of S6K1 at its hydrophobic motif. Phosphorylation results in S6K1 dissociation, activation, and subsequent phosphorylation of its translational targets, including eIF4B, which is then recruited into the complex in a phosphorylationdependent manner. Thus, the eIF3 preinitiation complex acts as a scaffold to coordinate a dynamic sequence of events in response to stimuli that promote efficient protein synthesis.
Introduction
Signal transduction pathways modulate cellular processes in eukaryotic cells in response to a variety of stimuli. The ability of a cell to respond to these stimuli depends in part on production of specific effector proteins. Traditionally, it was thought that the change in the proteome occurred as a result of transcriptional activity. However, we now know that regulating translation of specific messages is another way of altering protein production ( mTOR regulates the function of eIF4E by regulating the phosphorylation of the eIF4E inhibitory proteins, 4E binding proteins (4E-BPs). Phosphorylation of 4E-BP1 promotes its dissociation from eIF4E bound to the mRNA 7-methylguanosine cap structure, allowing for recruitment of eIF4G and eIF4A. eIF3, 40S ribosomal subunits, and the ternary complex (eIF2/Met-tRNA/ GTP) are also recruited to the cap, resulting in the assembly of the translation preinitiation complex (PIC) (for review, see Hay and Sonenberg, 2004) . It is unclear how eIF4B, an essential regulatory subunit of the helicase eIF4A, is recruited to the PIC. mTOR initiates S6K activation in response to cellular energy status, nutrient levels, and mitogens. Full and sustained S6K activation requires additional inputs by PI3K-dependent and -independent mechanisms and requires multiple growth-factor-induced phosphorylation events ( Here, we present a connection between the mTOR/ S6K1 pathway and translation initiation. We show that the eIF3 complex acts as a scaffolding platform that associates with mTOR and S6K1 in a growth-factorand rapamycin-sensitive manner, with mTOR associating with the eIF3 translation preinitiation complex and S6K1 dissociating from the eIF3 complex upon hormone or mitogenic stimulation. This sequence of events promotes the coordinated phosphorylation and activation of S6K1 and the phosphorylation of the 40S ribosomal protein S6 and eIF4B, a process that was previously unclear. Phosphorylation of eIF4B then contributes to its association with the translation preinitiation complex, where it is predicted to partner with eIF4A to form a fully functional mRNA helicase (Rogers et al., 1999 (Rogers et al., , 2001 ). The results presented here demonstrate a role for eIF4B phosphorylation in stimulating its recruitment to the translation preinitiation complex and uncover a regulated mechanism by which mTOR and S6K1 signaling is integrated into the process of translation initiation.
Results

Purification of eIF3-Complex Subunits as S6K1 Binding Proteins
In order to identify novel ways by which S6Ks might regulate protein translation, we sought to purify S6K1-associated proteins by employing the tandem-affinity purification (TAP) approach. We stably introduced pBABE vector expressing S6K1 with a dual HA and Protein A epitope tag into HEK293E cells and purified the associated proteins by a two-step procedure. S6K1-interacting proteins were eluted with MgCl 2 from the HA column in the second step of the purification as previously described (Ballif et al., 2004 ) and separated by SDS-polyacrylamide gel electrophoresis. The gel was stained with Coomassie brilliant blue, revealing a number of proteins that interacted with S6K1 but not with Protein A alone ( Figure 1A ). Protein bands were excised and analyzed by mass spectrometry. Two of these proteins were identified as subunits p40 and p47 of the translation initiation factor eIF3 complex (eIF3h and eIF3f). The copurification of the eIF3-complex subunits was also confirmed by other immunoprecipitations in which we identified core subunits eIF3c and eIF3b, as well as eIF3e complexed with S6K1 in growing HEK293E cells (data not shown).
The Interaction of the eIF3 Complex and S6K1 Is Regulated by Hormones, Mitogens, Phorbol Esters, Amino Acids, and Rapamycin After identifying members of the eIF3 complex in the S6K1 bound fraction by TAP, we set out to confirm this interaction and investigate its regulation. As shown in Figure 1B , HA-S6K1 coimmunoprecipitated with the core subunits b and c of the eIF3 complex under serum-starved conditions in HEK293E cells. Strikingly, this interaction was potently disrupted by insulin stimulation. Moreover, pretreatment with rapamycin restored the binding of eIF3 to S6K1.
We next verified that endogenous S6K1 exhibited the same regulated interaction with the eIF3 complex. Figure 1C shows that endogenous S6K1 coimmunoprecipitated with endogenous eIF3b under serum-starved and rapamycin-treated conditions but not after stimulation with insulin. The same pattern was observed when cells were stimulated with phorbol 12-myristate 13-acetate (PMA) or epidermal growth factor (EGF) and analyzed for the presence of S6K1 in eIF3b immunoprecipitates ( Figure 1D ). Again, the interaction observed under nonstimulated conditions was strongly disrupted by mitogen stimulation and restored by pretreatment with rapamycin. We also examined whether the S6K1/eIF3-complex interaction was observed in another cell type. As shown in Figure S1A in the Supplemental Data available with this article online, in serum-starved HeLa cells, S6K1 was associated with the eIF3 complex, and this interaction was disrupted by insulin addition and restored by rapamycin pretreatment. Thus, both endogenous and overexpressed S6K1 form a complex with eIF3 under conditions where S6K1 was not activated, and dissociation of S6K1 from the eIF3 complex by insulin, growth factors, or tumor-promoting phorbol esters was blocked by rapamycin. Finally, we determined whether amino acid availability, which also regulates mTOR signaling, modulated the S6K1/eIF3 interaction. As shown in Figure 1E , in nutrient-starved U2OS and HeLa cells, S6K1 was associated with the eIF3 complex, and this interaction was disrupted by amino acid addition and was restored by rapamycin pretreatment. Thus, nutrient availability also regulates the S6K1 and eIF3 interaction. Since our results suggested that the inactive, hypophosphorylated form of S6K1 associates with eIF3 and that activation correlates with its dissociation, we examined whether kinases that are involved in activation of S6K1 interact with the eIF3 complex. Specifically, we immunoprecipitated eIF3b from HEK293E cells and assayed for binding of endogenous Akt and PDK1. As depicted in Figure S1B , we found that Akt was not detected in eIF3b immunoprecipitates. Importantly, we also found that PDK1, which associates with the hydrophobic motif of S6K1 when it is phosphorylated ( Figure S1C and Frodin et al., 2002), did not interact with eIF3 ( Figure S1B ). Therefore, the association between S6K1 and the eIF3 complex appears to be specific and does not extend to other closely related AGC kinases. Additionally, we were able to detect some HA-S6K2 binding to eIF3; however, under the conditions of our experiments, its association was not regulated by insulin or rapamycin (data not shown). Thus, only S6K1 demonstrates a regulated interaction with the eIF3 complex. To further characterize the association of S6K1 with eIF3, the eIF3:40S preinitiation complex, and polysomes, we separated these complexes by sucrose-gradient fractionation of cell extracts. Fractionation of extracts from cells incubated with insulin ( Figure S2A Figure 2A . First, we examined the kinaseinactive (KD) mutant of S6K1 (containing a K100R mutation in the ATP binding site), the kinase-inactive TOS-motif mutant (F5A), and the kinase-inactive T229A mutant (containing a mutation at the phosphorylation site within the activation loop). As shown in Figure 2B , we found that, unlike the regulated interaction between wild-type S6K1 and eIF3, the kinase-inactive mutants of S6K1 bound constitutively to the eIF3 complex. The results with the F5A-S6K1 mutant also demonstrate that the binding of S6K1 to the eIF3 complex is not mediated by the TOS motif. These data are consistent with the observation that S6K1 phosphorylation, which correlates with its activation, promotes its dissociation from the eIF3-PIC.
Mutation of the TOS motif or the activation loop of S6K1 prevents phosphorylation of T389 (the hydrophobic motif), an important mTOR-regulated phosphorylation site necessary for its activation. We therefore hypothesized that the interaction between eIF3-PIC and S6K1 might be sensitive to mTOR-modulated S6K1 T389 phosphorylation. Thus, we investigated whether mutations at this site would affect the S6K1:eIF3-PIC interaction. The T389E mutation mimics phosphorylation of the hydrophobic motif and renders the kinase more active under basal conditions, still partially responsive to growth factors, and partially rapamycin resistant (see lower panel of Figure 2C and Schalm et al., 2005). As shown in Figure 2C , the T389E mutation greatly reduced eIF3 association with S6K1 under all conditions, similar to the behavior of activated S6K1. Importantly, the T389A mutation had the opposite effect compared to the T389E mutation: the T389A mutant constitutively bound to eIF3-PIC in a manner similar to the kinase-dead and F5A mutants. Therefore, the interaction between S6K1 and eIF3-PIC appears to be regulated by mTOR-dependent phosphorylation of S6K1 at T389.
We confirmed the contribution of S6K1 T389 phosphorylation to binding eIF3-PIC in the context of other mutations. We previously identified a stretch of three arginine residues in the C terminus of S6K1 that mediates an inhibitory effect on T389 phosphorylation, as mutation of these arginine residues to alanines (R3A) rescued the inhibition brought about by the F5A mutation and rendered the kinase rapamycin resistant (Schalm et al., 2005) . As shown in Figure 2D , a combination of the F5A and R3A mutations allowed S6K1 to bind to eIF3b under basal conditions and dissociate from eIF3 after insulin stimulation. However, because the F5A-R3A mutant is rapamycin resistant, pretreatment with rapamycin did not restore the association between S6K1 and eIF3. Significantly, the combination of F5A-R3A and the hydrophobic-motif mutation T389E (F5A-389E-R3A) dramatically reduced S6K1 binding to eIF3, similar to T389E mutation alone. Finally, the K100R-T389E mutant, which is catalytically inactive but carries a phosphomimetic mutation at the hydrophobic motif, does not interact with the eIF3 complex ( Figure  2E ). Therefore, the activation of S6K1 is not required per se for dissociation of S6K1 from the eIF3-PIC scaffold. This interaction appears to be regulated by phosphorylation of T389.
The eIF3-PIC Interacts with mTOR/Raptor
Because our data pointed to the involvement of mTORmediated T389 phosphorylation in the ability of S6K1 to dissociate from eIF3-PIC, we tested the possibility that mTOR, in association with its binding partner raptor, would also be part of the eIF3-PIC. To test this hypothesis, HEK293E cells were transfected with AUtagged mTOR and myc-raptor. Cells were lysed, and the complexes were immunoprecipitated using antibodies against the endogenous eIF3b and eIF3c. To our surprise, not only did mTOR and raptor coimmunoprecipitate with the eIF3 complex, but the interaction between mTOR/raptor and eIF3-PIC followed the pattern opposite of that of S6K1. Raptor and mTOR, which were weakly associated with eIF3 under serum-starved and rapamycin-treated conditions, bound strongly to eIF3c immunocomplexes following insulin stimulation ( Figure 3A) . Pretreatment with rapamycin reduced the insulin-mediated binding of mTOR/raptor to the eIF3 complex to basal levels. Similar results were obtained when immunoprecipitating endogenous raptor and mTOR ( Figure 3B ), although when monitoring endogenous proteins we noted lower levels of raptor binding in unstimulated or rapamycin-treated conditions. Therefore, upon insulin treatment, mTOR/raptor associates with eIF3-PIC, whereas S6K1 dissociates from the complex. To further characterize the interaction of mTOR with eIF3, eIF3:40S preinitiation complex, and polysomes, we separated these complexes by sucrose-gradient fractionation as shown and discussed for S6K1 ( Figure  S2 ). Importantly, unlike S6K1, we detected increased levels of mTOR copurifying with both low-and highmolecular-weight eIF3-containing complexes from cells incubated with insulin but not insulin plus rapamycin ( Figure S2C ; compare low-density fractions 4 and 5 to medium-density fractions 13 and 14). Taken together, these data suggest that the eIF3-PIC acts as a dynamic scaffold for mTOR and S6K1. 
The eIF3-PIC Interacts with S6K1 Targets
Since inactive S6K1 is docked at the eIF3 complex prior to agonist-induced translation initiation, we hypothesized that nutrients and mitogens serve to bring S6K1 near its translational targets. Hence, when activated, the tightly associated S6K1 is released from the eIF3 complex and is then able to phosphorylate these proximally associated proteins that regulate protein synthesis. To examine this possibility, we investigated whether the eIF3 complex associates with the 40S ribosome and eIF4B, which are targets of S6K1. As shown in Figure 4A , in addition to free eIF3, a portion of eIF3 was always associated with the 40S ribosome under our experimental conditions as monitored by immunoblotting eIF3 immunoprecipitates with antibody recognizing 40S ribosomal protein S6 (also see Figure S2 ), but increased S6 phosphorylation was only observed under conditions where S6K1 was phosphorylated and released from the eIF3-PIC. Interestingly, the association of eIF4B with the eIF3-PIC, as monitored by immunoblotting eIF3b immunoprecipitates with antibody recognizing eIF4B, was observed in insulin-stimulated but not serum-starved cells. Regulated association of eIF4B with the PIC had not been previously described. Furthermore, the insulin-stimulated interaction was potently disrupted by rapamycin treatment, suggesting that this interaction may also be regulated by posttranslational events. Therefore, when S6K1 is activated, its release from the eIF3 complex correlates with S6 phosphorylation and the association of eIF4B. Previous studies have been unable to determine a role for eIF4B phosphorylation. To test the hypothesis that phosphorylation of eIF4B by S6K1 leads to its recruitment to the eIF3-PIC, we used eIF4B phosphorylation mutants, nonphosphorylatable S422A, and phosphomimetic S422D. As depicted in Figure 4B , the S422A mutant was unable to associate with the eIF3-PIC under all conditions. Conversely, the S422D mutant constitutively bound to eIF3-PIC. Therefore, phosphorylation of eIF4B by activated S6K1 promotes its association with the translation preinitiation complex.
The T389A Mutant of S6K1 Prevents eIF4B Binding to the eIF3-PIC and the 7-Methylguanosine Cap Complex
We wanted to support the hypothesis that S6K1 activation and release from the eIF3-PIC was needed for subsequent phosphorylation of S6 and phosphorylation and association of eIF4B with the eIF3 complex. To do this, we overexpressed an inactive allele of S6K1 that is constitutively bound to eIF3-PIC to determine whether it would exhibit dominant-inhibitory activity and thus prevent binding or phosphorylation of S6K1 targets. As shown in Figure 4C , overexpression of T389A S6K1 inhibited the binding of eIF4B to eIF3-PIC after insulin stimulation. Phosphorylation of the 40S ribosomal S6 protein associated with eIF3 immunoprecipitates was also decreased when T389A S6K1 was expressed relative to phosphorylation of total cellular S6. We also determined whether T389A S6K1 overexpression blocked the recruitment of S6K1 targets to the 7-methylguanosine cap complex. As shown in Figure  4D , upon insulin treatment, T389A S6K1 prevented eIF4B binding to the 7-methylguanosine cap complex and decreased S6 phosphorylation. However, the binding of eIF4G, 4E-BP1, and eIF4E, which are not S6K1 targets, was unaffected. Importantly, the binding of eIF4G to the 7-methylguanosine cap complex correlated with the recruitment of mTOR/raptor and phosphorylation and release of 4E-BP1.
Temporal Association of Translational Components with eIF3-PIC and the 7-Methylguanosine Cap Complex
Our data suggested that, following growth-factor addition, mTOR/raptor associates with the eIF3 complex and phosphorylates and initiates activation of S6K1, which reduces its affinity for the complex and allows it to phosphorylate downstream targets such as 40S ribosomal protein S6 and the helicase subunit eIF4B. Phosphorylation of eIF4B then promotes its association with the translation preinitiation complex. To provide additional support for this model, we characterized the temporal regulation of endogenous protein binding to eIF3-PIC. First, we found that mTOR/raptor rapidly associated with eIF3-PIC within minutes of insulin stimulation. This correlated nicely with insulin-stimulated phosphorylation of S6K1 and its dissociation from the eIF3 complex ( Figure 5A ).
As shown in Figure 5A , maximal S6 phosphorylation lagged behind the phosphorylation and dissociation of S6K1 from the eIF3 complex. Treatment with rapamycin restored the binding of S6K1 to eIF3. Under these lysis conditions, the 40S subunit protein S6 appeared to coimmunoprecipitate with eIF3 throughout the time course. However, our sucrose-gradient fractionation analysis suggests that this represents a pool of free eIF3 and eIF3:40S subunits ( Figure S2 ) as previously described (Miyamoto et al., 2005) . Finally, we show that the binding of eIF4B with the eIF3-PIC correlated with its maximal phosphorylation, and also the maximal phosphorylation of S6-in other words, following phosphorylation, release, and the subsequent activation of S6K1 ( Figure 5A ).
We next investigated whether the association of proteins to eIF3-PIC occurred while it was docked at the cap complex. As shown in Figure 5B , we found that eIF3 was associated with the 7-methylguanosine cap complex with or without insulin, and in the presence of rapamycin, under our purification conditions. Previous studies have suggested that eIF3 is recruited to the 7-methylguanosine cap complex with eIF4G. We show, however, that overexpression of the TOS-motif mutant Figure S3A ). Furthermore, both eIF4E and the eIF3 complex could be eluted from the cap structure with free m 7 GTP ( Figure S3C ). We observed that eIF4G binds to the cap complex in timedependent fashion upon insulin stimulation, whereas 4E-BP1 shows time-dependent dissociation from the cap, both of which were rapamycin sensitive. eIF4E, on the other hand, is constitutively present at the cap complex. These data suggest that eIF3 may interact with eIF4E. Given our data, we suggest a model where the multiprotein eIF3 complex possesses binding sites for eIF4E, eIF4G, mTOR/raptor, S6K1, and likely other proteins that regulate translation initiation. Future work will be needed to define the molecular basis for these interactions. The association of eIF3 with the preinitiation complex is likely stabilized following mTOR-dependent phosphorylation and release of 4E-BP1 and the subsequent recruitment of eIF4G. Importantly, in this assay, mTOR and eIF4B demonstrated time-dependent regulation of complex interaction upon insulin stimulation. These results are consistent with the model where recruitment of mTOR/raptor upon insulin stimulation not only serves to initiate S6K1 T389 phosphorylation and its dissociation, activation, and downstream signaling from the eIF3 complex but also results in bringing mTOR/raptor to the repressed eIF4E/4E-BP1 complex, where it phosphorylates 4E-BP1, thus promoting its dissociation. The scaffold protein eIF4G and associated proteins such as eIF4A then bind to the eIF4E/ cap complex to stabilize the eIF3-PIC, recruit additional translation factors, and thus promote translation initiation.
Insulin, Rapamycin, and Members of the mTOR Signaling Pathway Regulate Cap-Dependent Translation
Finally, we set out to determine whether the mTOR pathway components contribute in vivo to cap-depen- Figure 6B , insulin led to a 2-fold increase in cap-dependent over cap-independent translation rates in serum-deprived cells, and this effect was completely rapamycin sensitive. This suggested that the insulin-stimulated increase in cap-dependent translation was modulated by signaling through the mTOR pathway. To further define this observation, we measured the effect of mTOR on cap-dependent translation. As shown in Figure 6C , mTOR overexpression led to a dramatic increase in translation rates in growing cells. We next examined how overexpression of the downstream effectors of mTOR, eIF4E and S6K1, would affect capdependent translation. We observed that both eIF4E and S6K1 also enhanced cap-dependent translation relative to the control. To test our model that S6K1 association with the eIF3-PIC was important with regard to its role in translation initiation, we measured the effect of overexpressing the nonphosphorylatable T389A-S6K1 or F5A-S6K1 mutants, which bind constitutively to the complex. Overexpression of both mutants led to a decrease in translation, which was comparable to serum starvation or rapamycin treatment of growing cells. The use of both mutants also indicates that inhibition of translation was not due to competition of the overexpressed TOS motif within the T389A mutant with mTOR/raptor signaling to 4E-BP1, as the F5A mutant contains a TOS-motif mutation but still significantly interferes with translation. Overexpression of T389E mutant, which does not to bind the complex, did not have an effect on translation rates. Lastly, we tested the effect of eIF4B overexpression in this system. Overexpression of wild-type eIF4B enhanced cap-dependent translation. Additionally, overexpression of the mutant eIF4B S422D mimicking S6K1 phosphorylation had an even greater effect on cap-dependent translation. Overexpression of S422A-eIF4B mutant, which does not associate with the complex, had no effect on translation. Therefore, mTOR, S6K1, and eIF4B positively modulate cap-dependent translation.
Discussion
Until now, it was unclear how S6K1 participated in translation initiation. We have identified the eIF3-PIC as a dynamic scaffold for mTOR-and S6K1-mediated assembly of the translation initiation complex. The interaction between S6K1 and the eIF3-PIC is governed by the activating phosphorylation of S6K1 on the hydrophobic-motif residue T389. We have shown that phosphorylation of T389 is critical for the release of S6K1 from the eIF3 complex. However, it is not known whether T389 is a direct interface for interaction with this complex or whether the phosphorylation of T389 leads to a conformational change that disrupts S6K1 and eIF3-PIC binding. Importantly, other hydrophobicmotif-containing AGC-family kinases do not appear to interact with the eIF3-PIC in unstimulated or stimulated cells. Additionally, PDK1, which participates in hydrophobic-motif interactions, does not interact with this scaffold. This is of importance as PDK1 association with S6K1 has been reported to be enhanced following phosphorylation of the hydrophobic motif (Frodin et al.,  2002) . Once phosphorylated by mTOR/raptor at T389, S6K1 would be released, become accessible, and interact with PDK1, which would then promote phosphorylation of the S6K1 activation loop (T229) (see Figure 7) . This would promote full activation of S6K1, and The series of results obtained in this study allow us to postulate the following model for the regulated assembly and activation of an efficient translation initiation complex by mTOR/raptor and S6K1 (Figure 7) . Under basal conditions, S6K1 is bound to the eIF3 complex, whereas mTOR association is greatly reduced. The interaction of mTOR and S6K1 with the eIF3 complex is dynamic and sensitive to serum starvation, insulin stimulation, and/or rapamycin treatment. The molecular details of this interaction have yet to be defined. The fact that rapamycin treatment reverses the effect of insulin or growth-factor treatment is important as it demonstrates that the observations made here are not simply related to starvation and stimulation conditions but are also relevant to conditions where the mTOR pathway is inappropriately activated and translation rates upregulated. For example, in cancers with activated PI3 kinase or loss of PTEN function, rapamycin should be very effective at reversing the biological consequences of inappropriately activated S6K1 signaling.
Thus, following an activating signal, such as insulin stimulation, mTOR/raptor is recruited to the eIF3-PIC, leading to phosphorylation of the bound and inactive S6K1 on T389. Phosphorylated S6K1 is then released from the eIF3 complex. Based on our sucrose-gradient profiles, 7-methylguanosine cap-bead pull-downs, and m 7 GTP elution experiments, the eIF3 to which S6K1 binds appears not to be associated with 40S subunits and may be "free" and/or loosely associated with eIF4E bound to the mRNA 5# cap. This observation has further significance in that it also places the recruited mTOR/raptor into position to phosphorylate 4E-BP1, the eIF4E bound suppressor of cap-dependent transla- Under basal conditions, S6K1 is associated with the eIF3 complex. Upon mitogen stimulation, an activation complex is formed in which mTOR/raptor is recruited to the eIF3 complex and phosphorylatea S6K1 and 4E-BP1. Phosphorylation of S6K1 at T389 leads to its dissociation from the eIF3 complex (A). T389-phosphorylated S6K1 then binds to PDK1, which phosphorylates S6K1 at T229. The fully activated S6K1 then phosphorylates eIF4B and S6 (B). Phosphorylation of eIF4B at S422 promotes its association with the translation preinitiation complex. Concurrently, mTOR/raptor phosphorylates 4E-BP1 (A), which dissociates from the cap complex, allowing recruitment of the eIF4G scaffold to the cap bound eIF4E as part of the eIF4F translation initiation complex (B). This sequence of events leads to preinitiation-complex assembly and initiation of protein translation. tion. Thus the eIF3 complex acts as a scaffold allowing mTOR/raptor to promote the coordinated regulation of 4E-BP1 and S6K1 phosphorylation. Since PDK1 is not part of this scaffold complex, PDK1 must interact with T389-phosphorylated S6K1 after its dissociation, allowing for T229 phosphorylation within its activation loop and catalytic activation ( Figure 7B ). Activated S6K1 then phosphorylates eIF4B and the 40S ribosomal subunit protein S6. The S6K1 substrate eIF4B, when phosphorylated, is then recruited to the eIF3:40S ribosomal subunit preinitiation complex. The recruitment of phosphorylated eIF4B is not dependent upon the recruitment of eIF4G and the eIF4A helicase as the nonphosphorylatable 4E-BP1 (F114A) blocks insulin-stimulated recruitment of eIF4G to the cap complex without affecting recruitment of eIF4B. eIF4B recruitment is, however, antagonized by nonphosphorylatable mutants of S6K1, whereas eIF4G binding to the cap complex is not. Previous studies have shown that the helicase subunit eIF4A has low activity in the absence of eIF4B ( 
Antibodies
Anti-myc monoclonal antibodies were purchased from Charles River Laboratories. Anti-HA monoclonal antibodies were kindly provided by Margaret Chou (University of Pennsylvania, Philadelphia). Anti-AU1 mononoclonal antibodies were from Covance. Anti-phospho-S6 antibodies were kindly provided by Morris Birnbaum (University of Pennsylvania and HHMI, Philadelphia). Anti-eIF3, anti eIF4G, anti-mTOR, and 4E-BP1 antibodies were purchased from Santa Cruz Biotechnology. Anti-p70S6K antibody was described previously (Romanelli et al., 1999) . Anti-Akt, anti-S6K1 T389, anti-S6, anti-eIF4E, anti-raptor, anti-4E-BP1 P-S65, anti-eIF4B, and P-S422 antibodies were purchased from Cell Signaling Technology. Anti-PDK1 antibodies were from Upstate USA, Inc. For immunoblotting, anti-rabbit, anti-mouse, and anti-goat horseradish peroxidase (HRP) conjugated antibodies were purchased from Amersham, Chemicon, and Santa Cruz Biotechnology, respectively.
Immune Complex Kinase Assay S6K1 kinase assays were done as previously described (Romanelli et al., 1999).
Tandem-Affinity Purification
Ten 15 cm plates of stably transfected, growing cells were lysed, and lysates were incubated with IgG bead columns (Sigma) for 2 hr at 4°C. IgG columns were washed twice with 10 ml lysis buffer and equilibrated with 50 mM Tris (pH 8.0). TEV cleavage reaction was performed as described by the manufacturer (Invitrogen Life Technologies) for 2 hr at 4°C. The eluant was incubated with HAantibody coupled to Affigel matrix (Bio-Rad) for 1 hr at 4°C. The matrix was washed with 10 ml lysis buffer. The associated proteins were eluted with 1 M MgCl 2 , 50 mM HEPES (pH 7.2) followed by TCA precipitation. Precipitates were washed with acetone and resolved using 4%-12% SDS-PAGE. 
Bicistronic Luciferase Assay
Mass Spectrometry
Gel bands were excised, diced, and subjected to in-gel digestion with sequencing grade trypsin (Promega, 12.5 ng/l) in 50 mM ammonium bicarbonate overnight at 37°C. Peptides were extracted with 50% acetonitrile (ACN), 5% formic acid (FA) and then dried. Peptides were then resuspended in 2.5% ACN, 5% FA and loaded using an autosampler onto a microcapillary column (100 m × 12 cm) packed with reverse-phase MagicC18 material (5 m, 200 Å, Michrom Bioresources, Inc.). Elution was achieved with a 5%-35% ACN (0.1% FA) gradient over 60 min, after a 20 min isocratic loading at 2.5% ACN, 0.5% FA. Mass spectra were acquired on a LCQDeca XP (Thermo Electron) over the entire run using eight MS/MS scans following each survey scan. Raw data were searched for fully tryptic peptides against the NCBI nonredundant human database using Sequest software and a mass allowance of 2 Da. 
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